The efficacy of topical intralesional BCG-PSN injection in the treatment of erosive oral lichen planus: A randomized controlled trial

Journal of Oral Pathology and Medicine

Volumn 38, Issue 7, 2009, Pages 551-558

  Xiong, C ^a   Li, Q ^a   Lin, M ^b   Li, X ^b   Meng, W ^a   Wu, Y ^a   Zeng, X ^b   Zhou, H ^b   Zhou, G ^c  

^a SICHUAN UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

^c WUHAN UNIVERSITY   (China)

Author keywords

Erosive oral lichen planus; Immunomodulators; Intralesional injection; Polysaccharide nucleic acid fraction of bacillus Calmette Guerin

Indexed keywords

BCG VACCINE; IMMUNOMODULATING AGENT; NUCLEIC ACID; POLYSACCHARIDE; TOPICAL AGENT; TRIAMCINOLONE ACETONIDE;

ADULT; ARTICLE; BURNING SENSATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; LICHEN PLANUS; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; SHORT COURSE THERAPY; SWELLING; TREATMENT RESPONSE; VISUAL ANALOG SCALE;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, TOPICAL; ADULT; FEMALE; FOLLOW-UP STUDIES; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INJECTIONS, INTRALESIONAL; LICHEN PLANUS, ORAL; MALE; MIDDLE AGED; MYCOBACTERIUM BOVIS; NUCLEIC ACIDS; POLYSACCHARIDES, BACTERIAL; PRECANCEROUS CONDITIONS; SINGLE-BLIND METHOD; STATISTICS, NONPARAMETRIC; TRIAMCINOLONE ACETONIDE;

EID: 70350320680     PISSN: 09042512     EISSN: 16000714     Source Type: Journal    
DOI: 10.1111/j.1600-0714.2009.00796.x     Document Type: Article

References (51)

1. Edwards PC, Kelsch R. Oral lichen planus: clinical presentation and management. J Can Dent Assoc 2002; 68: 494-499
2. Warnakulasuriya S, Johnson NW, Van Der Waal I. Nomenclature and classification of potentially malignant disorders of the oral mucosa. J Oral Pathol Med 2007; 36: 575-580
3. Lodi G, Scully C, Carrozzo M, et al. Current controversies in oral lichen planus: report of an international consensus meeting. Part 1. Viral infections and etiopathogenesis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2005; 100: 40-51. (Pubitemid 40813390)
4. Thornhill MH. Immune mechanisms in oral lichen planus. Acta Odontol Scand 2001; 59: 174-177
5. Carbone M, Goss E, Carrozzo M, et al. Systemic and topical corticosteroid treatment of oral lichen planus: a comparative study with long-term follow-up. J Oral Pathol Med 2003; 32: 323-329
6. Thongprasom K, Luengvisyt P, Wongwatanakjj A, Boonjatturus C. Clinical evaluation in treatment of oral lichen planus with topical fluocinolone acetonide: a 2-year follow-up. J Oral Pathol Med 2003; 32: 315-322
7. Lodi G, Scully C, Carrozzo M, et al. Current controversies in oral lichen planus: report of an international consensus meeting. Part 2. Clinical management and malignant transformation. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2005; 100: 164-178 (Pubitemid 41020782)
8. Valera FC, Queiroz R, Scrideli C, Tone LG, Anselmo- Lima WT. Evaluating budesonide efficacy in nasal polyposis and predicting the resistance to treatment. Clin Exp Allergy 2009; 39: 81-88
9. Feldman-Billard S, Heron E. Systemic tolerance of corticosteroid therapy in ophthalmology depending on the route of administration. J Fr Ophtalmol 2008; 31: 1026-1036
10. Levin C, Maibach HI. Topical corticosteroid-induced adrenocortical insufficiency: clinical implications. Am J Clin Dermatol 2002; 3: 141-147
11. Thongprasom K, Luangjarmekorn L, Sererat T, Taweesap W. Relative efficacy of fluocinolone acetonide compared with triamcinolone acetonide in treatment of oral lichen planus. J Oral Pathol Med 1992; 21: 456-458
12. Gonzalez-Garcia A, Diniz-Freitas M, Gandara-Vila P, Blanco-Carrion A, Garcia-Garcia A, Gandara-Rey J. Triamcinolone acetonide mouth rinses for treatment of erosive oral lichen planus: efficacy and risk of fungal overinfection. Oral Dis 2006; 12: 559-565
13. Pels R, Sterry W, Lademann J. Clobetasol propionate - where, when, why? Drugs Today (Barc) 2008; 44: 547-557
14. Schoepe S, Schacke H, May E, Asadullah K. Glucocorticoid therapy-induced skin atrophy. Exp Dermatol 2006; 15: 406-420
15. Teelucksingh S, Balkaran B, Ganeshmoorthi A, Arthur P. Prolonged childhood Cushing's syndrome secondary to intralesional triamcinolone acetonide. Ann Trop Paediatr 2002; 22: 89-91.
16. Kumar S, Singh RJ, Reed AM, Lteif AN. Cushing's syndrome after intra-articular and intradermal administration of triamcinolone acetonide in three pediatric patients. Pediatrics 2004; 113: 1820-1824
17. Iglesias P, Gonzalez J, Diez JJ. Acute and persistent iatrogenic Cushing's syndrome after a single dose of triamcinolone acetonide. J Endocrinol Invest 2005; 28: 1019-1023
18. Foti C, Calogiuri G, Cassano N, Buquicchio R, Vena GA. Contact allergy to topical corticosteroids: update and review on cross-sensitization. Recent Pat Inflamm Allergy Drug Discov 2009; 3: 33-39
19. Byrd JA, Davis MD, Bruce AJ, Drage LA, Rogers RS III. Response of oral lichen planus to topical tacrolimus in 37 patients. Arch Dermatol 2004; 104: 1508-1512
20. Van Rossum EF, Koperr JW, Van Der Beld AW, et al. Identification of the BclI polymorphism in the glucocorticoid receptor gene: association with sensitivity to glucocorticoids in vivo and body mass index. Clin Endocrinol 2003; 59: 585-592
21. Charmandari E, Kino T, Ichijo T, Chrousos GP. Generalized glucocorticoid resistance: clinical aspects, molecular mechanisms, and implications of a rare genetic disorder. J Clin Endocrinol Metab 2008; 93: 1563-1572
22. Zhou G, Fan MW, Liu JY. Regulation of BCG-polysaccharide nucleic acid on Thl / Th2 cytokines from peripheral blood mononuclear cells in oral lichen planus. Chin J Dent Res 2004; 7: 5-10.
23. Piboonniyom SO, Treister N, Pitiphat W, Woo SB. Scoring system for monitoring oral lichenoid lesions: a preliminary study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2005; 99: 696-703.
24. Kilpi A. Activation marker analysis of mononuclear cell inflitrates of oral lichen planus. Scand J Dent Res 1987; 95: 174-180
25. El-Zefzaf E, Abd-El-Razzak M, Ghoneim S, Abu-Azma N. Demonstration of T-cell subsets in oral lichen planus. Egypt Dent J 1994; 40: 633-638
26. Zhou XJ, Sugerman PB, Savage NW, Walsh LJ, Seymour GJ. Intra-epithelial CD8+ T cells and basement membrane disruption in oral lichen planus. J Oral Pathol Med 2002; 31: 23-27
27. Khan A, Farah CS, Savage NW, Walsh LJ, Harbrow DJ, Sugerman PB. Th1 cytokines in oral lichen planus. J Oral Pathol Med 2003; 32: 77-83.
28. Simark-Mattsson C, Jontell M, Bergenholtz G, Heyden M, Dahlgren UI. Distribution of interferon-gamma mRNA-positive cells in oral lichen planus lesions. J Oral Pathol Med 1998; 27: 483-488
29. Rodriguez-Nunez I, Blanco-Carrion A, Garcia AG, Rey JG. Peripheral T-cell subsets in patients with reticular and atrophic-erosive oral lichen planus. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2001; 91: 180-188
30. Rey JG, Garcia AG, Blanco-Carrion A, Gandara-Vila P, Rodriguez-Nunez I. Cellular immune alterations in fiftytwo patients with oral lichen planus. Med Oral 2001; 6: 246-262
31. Villarroel-Dorrego M, Correnti M, Delgado R, Tapia FJ. Oral lichen planus: immunohistology of mucosal lesions. J Oral Pathol Med 2002; 31: 410-414
32. Charazinska-Carewicz K, Ganowicz E, Krol M, Gorska R. Assessment of the peripheral immunocompetent cells in patients with reticular and atrophic-erosive lichen planus. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2008; 105: 202-205
33. Carrozzo M, Uboldi-De-Capei M, Dametto E, et al. Tumor necrosis factor-alpha and interferon-gamma polymorphisms contribute to susceptibility to oral lichen planus. J Invest Dermatol 2004; 122: 87-94.
34. Tao XA, Li CY, Rhodus NL, Xia J, Yang XP, Cheng B. Simultaneous detection of IFN-gamma and IL-4 in lesional tissues and whole unstimulated saliva from patients with oral lichen planus. J Oral Pathol Med 2008; 37: 83-87
35. Simark-Mattsson C, Bergenholtz G, Jontell M, et al. Distribution of interleukin-2, -4, -10, tumour necrosis factor-alpha and transforming growth factor-beta mRNAs in oral lichen planus. Arch Oral Biol 1999; 44: 499-507.
36. Rhodus NL, Cheng B, Bowles W, Myers S, Miller L, Ondrey F. Proinflammatory cytokine levels in saliva before and after treatment of (erosive) oral lichen planus with dexamethasone. Oral Dis 2006; 12: 112-116
37. Ordway D, Henao-Tamayo M, Shanley C, et al. Influence of Mycobacterium bovis BCG vaccination on cellular immune response of guinea pigs challenged with Mycobacterium tuberculosis. Clin Vaccine Immunol 2008; 15: 1248-1258
38. Soares AP, Scriba TJ, Joseph S, et al. Bacillus Calmette- Guérin vaccination of human newborns induces T cells with complex cytokine and phenotypic profiles. J Immunol 2008; 180: 3569-3577
39. Sharma P, Bajorin DF, Jungbluth AA, Herr H, Old LJ, Gnjatic S. Immune responses detected in urothelial carcinoma patients after vaccination with NY-ESO-1 protein plus BCG and GM-CSF. J Immunother 2008; 31: 849-857
40. Kapoor S. Mycobacterium bovis bacillus Calmette-Guerin therapy is a potent immunostimulator for management of systemic malignancies. Clin Vaccine Immunol 2008; 15: 277-283
41. Colombel M, Saint F, Chopin D, Malavaud B, Nicolas L, Rischmann P. The effect of ofloxacin on bacillus calmetteguerin induced toxicity in patients with superficial bladder cancer: results of a randomized, prospective, double-blind, placebo controlled, multicenter study. J Urol 2006; 176: 935-939
42. Giri PK, Schorey JS. Exosomes derived from M. Bovis BCG infected macrophages activate antigen-specific CD4+ and CD8+ T cells in vitro and in vivo. PLoS ONE 2008; 3: e2461.
43. Mazzola TN, Da Silva MT, Moreno YM, et al. Robust gammadelta + T cell expansion in infants immunized at birth with BCG vaccine. Vaccine 2007; 25: 6313-6320
44. Rook GA. Th2 cytokines in susceptibility to tuberculosis. Curr Mol Med 2007; 7: 327-337
45. Oss ML, Cr Lambeth MR, Aidwell FE. Human gammadelta T cells modulate the mite allergen-specific Thelper type 2-skewed immunity. Clin Exp Allergy 2007; 37: 1681-1687
46. Sheikhi A, Nazarian M, Khadem-Al-Melleh A, et al. In-vitro effects of Mycobacterium bovis BCG-lysate and its derived heat shock proteins on cytokines secretion by blood mononuclear cells of rheumatoid arthritis patients in comparison with healthy controls. Int Immunopharmacol 2008; 8: 887-892
47. Bastos RG, Johonson WC, Mwanggi W, Brown WC, Goff WL. Bovine NK cells acquire cytotoxic activity and produce IFN-gamma after stimulation by Mycobacterium bovis BCG- or Babesia bovis-exposed splenic dendritic cells. Vet Immunol Immunopathol 2008; 124: 302-312
48. Xia J, Li C, Hong Y, Yang LL, Huang YL, Cheng B. Short-term clinical evaluation of intralesional triamcinolone acetonide injection for ulcerative oral lichen planus. J Oral Pathol Med 2006; 35: 327-331
49. Laeijendecker R, Tank B, Dekker SK, et al. A comparison of treatment of oral lichen planus with topical tacrolimus and triamcinolone acetonide ointment. Acta Derm Venereol 2006; 86: 227-229
50. Gorouhi F, Solhpour A, Beitollahi JM, et al. Randomized trial of pimecrolimus cream versus triamcinolone acetonide paste in the treatment of oral lichen planus. J Am Acad Dermatol 2007; 57: 806-813
51. Jeal W, Faulds D. Triamcinolone acetonide. A review of its pharmacological properties and therapeutic efficacy in the management of allergic rhinitis. Drugs 1997; 53: 257-280 (Pubitemid 27073116)